Uroxatral
NDC 59212-200 · Advanz Pharma (US) Corp.
Packages
59212-200-10 — 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (59212-200-10)
59212-200-30 — 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (59212-200-30)
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
29300-155 — Alfuzosin hydrochloride, 43353-945 — Alfuzosin hydrochloride, 47335-956 — Alfuzosin Hydrochloride, 51655-087 — Alfuzosin Hydrochloride, 51655-432 — Alfuzosin Hydrochloride, 51655-967 — Alfuzosin hydrochloride, 57237-114 — Alfuzosin Hydrochloride, 60505-2850 — Alfuzosin Hydrochloride, 63629-9155 — Alfuzosin hydrochloride, 65862-249 — Alfuzosin Hydrochloride, 69097-844 — Alfuzosin Hydrochloride, 71335-2146 — Alfuzosin Hydrochloride, 71335-2578 — Alfuzosin Hydrochloride, 72162-1449 — Alfuzosin Hydrochloride, 76282-302 — Alfuzosin hydrochloride, 84386-153 — Alfuzosin Hydrochloride
Poisoning, adverse-effect and underdosing codes for this drug
The ICD-10-CM Table of Drugs and Chemicals carries these diagnosis codes for this drug — a drug-name match derived from FDA's product name and the Table of Drugs and Chemicals, not a CMS-published pairing.
T44.8X1 — Poisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), T44.8X2 — Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, T44.8X3 — Poisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, T44.8X4 — Poisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, T44.8X5 — Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, T44.8X6 — Underdosing of centrally-acting and adrenergic-neuron-blocking agents